Patents by Inventor Andrew Louis McIver
Andrew Louis McIver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220002335Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.Type: ApplicationFiled: January 27, 2021Publication date: January 6, 2022Inventors: John Henry BOUGHER, III, Ramamurty V S CHANGALVALA, Aaron Leigh DOWNEY, John C. DRACH, Ernest Randall LANIER, JR., Andrew Louis MCIVER, Bradley David ROBERTSON, Dean Wallace SELLESETH, Phiroze Behram SETHNA, Leroy TOWNSEND, Roy W. WARE
-
Patent number: 10941175Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.Type: GrantFiled: August 6, 2019Date of Patent: March 9, 2021Assignees: Chimerix, Inc., The Regents of the University of MichiganInventors: John Henry Bougher, III, Ramamurty V S Changalvala, Aaron Leigh Downey, John C. Drach, Ernest Randall Lanier, Jr., Andrew Louis McIver, Bradley David Robertson, Dean Wallace Selleseth, Phiroze Behram Sethna, Leroy Townsend, Roy W. Ware
-
Patent number: 10836759Abstract: A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.Type: GrantFiled: June 21, 2017Date of Patent: November 17, 2020Assignees: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Matthew Brian Boxer, Xiaodong Wang, Kyle Ryan Brimacombe, Mindy Irene Emily Davis, Yuhong Fang, Matthew Hall, Ajit Jadhav, Surendra Karavadhi, Li Liu, Natalia Martinez, Andrew Louis McIver, Rajan Pragani, Jason Matthew Rohde, Anton Simeonov, Wei Zhao, Min Shen
-
Patent number: 10703746Abstract: Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.Type: GrantFiled: December 22, 2015Date of Patent: July 7, 2020Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Matthew Brian Boxer, Jason Matthew Rohde, Rajan Pragani, Li Liu, Mindy Irene Emily Davis, Kyle Ryan Brimacombe, Min Shen, Anton Simeonov, Surendra Karavadhi, Daniel Jason Urban, Ajit Jadhav, Xiaodong Wang, Andrew Louis McIver
-
Publication number: 20200199167Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.Type: ApplicationFiled: August 6, 2019Publication date: June 25, 2020Inventors: John Henry BOUGHER, III, Ramamurty V S CHANGALVALA, Aaron Leigh DOWNEY, John C. DRACH, Ernest Randall LANIER, Jr., Andrew Louis MCIVER, Bradley David ROBERTSON, Dean Wallace SELLESETH, Phiroze Behram SETHNA, Leroy TOWNSEND, Roy W. WARE
-
Patent number: 10407457Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.Type: GrantFiled: May 18, 2017Date of Patent: September 10, 2019Assignees: Chimerix, Inc., The Regents of the University of MichiganInventors: John Henry Bougher, III, Ramamurty V S Changalvala, John C. Drach, Ernest Randall Lanier, Jr., Andrew Louis McIver, Bradley David Robertson, Dean Wallace Selleseth, Phiroze Behram Sethna, Leroy Townsend, Roy W. Ware
-
Publication number: 20190241551Abstract: A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.Type: ApplicationFiled: June 21, 2017Publication date: August 8, 2019Inventors: Matthew Brian BOXER, Xiaodong WANG, Kyle Ryan BRIMACOMBE, Mindy Irene Emily DAVIS, Yuhong FANG, Matthew HALL, Ajit JADHAV, Surendra KARAVADHI, Li LIU, Natalia MARTINEZ, Andrew Louis MCIVER, Rajan PRAGANI, Jason Matthew ROHDE, Anton SIMEONOV, Wei ZHAO, Min SHEN
-
Publication number: 20190071434Abstract: Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.Type: ApplicationFiled: December 22, 2015Publication date: March 7, 2019Inventors: Matthew Brian Boxer, Jason Matthew Rohde, Rajan Pragani, LI Liu, Mindy Irene Emily Davis, Kyle Ryan Brimacombe, Min Shen, Anton Simeonov, Surendra Karavadhi, Daniel Jason Urban, Ajit Jadhav, Xiaodong Wang, Andrew Louis McIver
-
Patent number: 9771330Abstract: Compounds of Formula I or II: are described, along with pharmaceutical compositions containing the same and methods of using such compounds for the treatment of cancer.Type: GrantFiled: November 22, 2013Date of Patent: September 26, 2017Assignee: The University of North Carolina at Chapel HillInventors: Xiaodong Wang, Weihe Zhang, Stephen V. Frye, Dmitri Kireev, Andrew Louis McIver, Jing Liu
-
Publication number: 20170253628Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.Type: ApplicationFiled: May 18, 2017Publication date: September 7, 2017Inventors: John Henry Bougher, III, Ramamurty V S Changalvala, Aaron Leigh Downey, John C. Drach, Ernest Randall Lanier, JR., Andrew Louis McIver, Bradley David Robertson, Dean Wallace Selleseth, Phiroze Behram Sethna, Leroy Townsend, Roy W. Ware
-
Patent number: 9708359Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.Type: GrantFiled: August 8, 2016Date of Patent: July 18, 2017Assignees: Chimerix, Inc., The Regents of the University of MichiganInventors: John Henry Bougher, III, Ramamurty V S Changalvala, Aaron Leigh Downey, John C. Drach, Ernest Randall Lanier, Jr., Andrew Louis McIver, Bradley David Robertson, Dean Wallace Selleseth, Phiroze Behram Sethna, Leroy Townsend, Roy W. Ware
-
Patent number: 9701706Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.Type: GrantFiled: November 22, 2016Date of Patent: July 11, 2017Assignees: Chimerix, Inc., The Regents of the University of MichiganInventors: John Henry Bougher, III, Ramamurty V S Changalvala, John C. Drach, Ernest Randall Lanier, Jr., Andrew Louis McIver, Bradley David Robertson, Dean Wallace Selleseth, Phiroze Behram Sethna, Leroy Townsend, Roy W. Ware